Evidence map›Paper›PMID 33185777›Full record

ArticleInternational journal of clinical oncology2021

Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan.

Seiji Mabuchi, Misa Yamamoto, Hiroko Murata, Takuya Yokoe, Junzo Hamanishi, Yoshito Terai, Hikaru Imatake, Yasushi Mabuchi, Taisuke Mori, Fuminori Kitada and 5 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Seiji MabuchiDepartment of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. smabuchi@naramed-u.ac.jp.
Misa YamamotoDepartment of Obstetrics and Gynecology, Osaka University, Suita, Osaka, Japan.
Hiroko MurataDepartment of Gynecologic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan.
Takuya YokoeDepartment of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Osaka, Japan.
Junzo HamanishiDepartment of Obstetrics and Gynecology, Kyoto University, Kyoto, Kyoto, Japan.
Yoshito TeraiDepartment of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Hikaru ImatakeDepartment of Obstetrics and Gynecology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Yasushi MabuchiDepartment of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Wakayama, Japan.
Taisuke MoriDepartment of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
Fuminori KitadaDepartment of Obstetrics and Gynecology, Suita Tokusyukai Hospital, Suita, Osaka, Japan.
Yasuhiro HashiguchiDepartment of Obstetrics and Gynecology, Nara Prefecture General Medical Center, Nara, Nara, Japan.
Akimasa TakahashiDepartment of Obstetrics and Gynecology, Shiga University of Medical Science, Otsu, Shiga, Japan.
Satoe FujiwaraDepartment of Obstetrics and Gynecology, Osaka Medical College, Takatsuki, Osaka, Japan.
Hirokazu NaoiDepartment of Obstetrics and Gynecology, Kaizuka City Hospital, Kaizuka, Osaka, Japan.
Sho MatsubaraDepartment of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe development of perforations or fistulas in the Gastrointestinal (GI) tract or genitourinary (GU) system is a serious adverse effect of bevacizumab. The aim of this study was to investigate the incidences of these GI/GU events as well as their association with previous radiotherapy (RT) in Japanese women with cervical cancer.

methodsWe conducted a written questionnaire survey among 14 gynecological institutions belonging to the Oncology Research Committee of the Obstetrical and Gynecological Society of Kinki District, Japan. The severity of GI/GU events was classified according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0. All data were extracted from survey responses and maintained in an Excel spreadsheet and summarized using descriptive statistics.

resultsThe information of 224 Japanese women with cervical cancer (152 recurrent and 72 advanced) who were treated with bevacizumab-containing chemotherapy was collected from 14 institutions. Of these, 65% had been previously treated with RT. GI/GU events of any grade developed in 25 (11.2%) patients, leading directly to death in 3 (1.3%) patients. When compared, the incidence of GI/GU events was higher in recurrent disease patients than in advanced disease patients (13.8% vs 5.6%, p = 0.0728). When examined according to the history of RT, the incidence of GI/GU events was greater in patients with a history of RT than in those without (14.5% vs 5.1%, p = 0.044).

conclusionMore than 10% of patients experience GI/GU events during or after receiving bevacizumab-containing chemotherapies. Prior RT is a risk factor for bevacizumab-associated GI/GU events.

Indexed as

Prostatic NeoplasmsUterine Cervical NeoplasmsBevacizumabFemaleHumansJapanMaleSurveys and QuestionnairesBevacizumabBevacizumabCervical cancerFistulaPerforationRisk factor

Identifiers

PMID33185777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.